News Updates

More Articles Back to Article

Novartis preps for new buyback round worth $11B

Novartis is slated to initiate a share buyback round with the goal of repurchasing up to approximately $11 billion worth of shares over a three-year period. The company is currently undergoing major restructuring and has plans of spinning off Sandoz, its generics and biosimilars business. Fierce Pharma (3/13)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!